These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 28886144)

  • 1. Pharmacological characterisation of S 47445, a novel positive allosteric modulator of AMPA receptors.
    Bretin S; Louis C; Seguin L; Wagner S; Thomas JY; Challal S; Rogez N; Albinet K; Iop F; Villain N; Bertrand S; Krazem A; Bérachochéa D; Billiald S; Tordjman C; Cordi A; Bertrand D; Lestage P; Danober L
    PLoS One; 2017; 12(9):e0184429. PubMed ID: 28886144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel dualistic profile of an allosteric AMPA receptor modulator identified through studies on recombinant receptors, mouse hippocampal synapses and crystal structures.
    Christiansen GB; Harbak B; Hede SE; Gouliaev AH; Olsen L; Frydenvang K; Egebjerg J; Kastrup JS; Holm MM
    Neuroscience; 2015 Dec; 310():709-22. PubMed ID: 26450748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
    Baumbarger PJ; Muhlhauser M; Zhai J; Yang CR; Nisenbaum ES
    J Pharmacol Exp Ther; 2001 Jul; 298(1):86-102. PubMed ID: 11408529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. S18986: a positive modulator of AMPA-receptors enhances (S)-AMPA-mediated BDNF mRNA and protein expression in rat primary cortical neuronal cultures.
    Lockhart BP; Rodriguez M; Mourlevat S; Peron P; Catesson S; Villain N; Galizzi JP; Boutin JA; Lestage P
    Eur J Pharmacol; 2007 Apr; 561(1-3):23-31. PubMed ID: 17331496
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different characteristics of AMPA receptor agonists acting at AMPA receptors expressed in Xenopus oocytes.
    Wahl P; Madsen U; Banke T; Krogsgaard-Larsen P; Schousboe A
    Eur J Pharmacol; 1996 Jul; 308(2):211-8. PubMed ID: 8840134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Heterogeneity and potentiation of AMPA type of glutamate receptors in rat cultured microglia.
    Hagino Y; Kariura Y; Manago Y; Amano T; Wang B; Sekiguchi M; Nishikawa K; Aoki S; Wada K; Noda M
    Glia; 2004 Jul; 47(1):68-77. PubMed ID: 15139014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological detection of AMPA receptor heterogeneity by use of two allosteric potentiators in rat hippocampal cultures.
    Sekiguchi M; Takeo J; Harada T; Morimoto T; Kudo Y; Yamashita S; Kohsaka S; Wada K
    Br J Pharmacol; 1998 Apr; 123(7):1294-303. PubMed ID: 9579722
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel allosteric potentiator of AMPA receptors: 4--2-(phenylsulfonylamino)ethylthio--2,6-difluoro-phenoxyaceta mide.
    Sekiguchi M; Fleck MW; Mayer ML; Takeo J; Chiba Y; Yamashita S; Wada K
    J Neurosci; 1997 Aug; 17(15):5760-71. PubMed ID: 9221774
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DRUG FOCUS: S 18986: A positive allosteric modulator of AMPA-type glutamate receptors pharmacological profile of a novel cognitive enhancer.
    Bernard K; Danober L; Thomas JY; Lebrun C; Muñoz C; Cordi A; Desos P; Lestage P; Morain P
    CNS Neurosci Ther; 2010 Oct; 16(5):e193-212. PubMed ID: 21050420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of a New Positive Allosteric Modulator of AMPA Receptors - PAM-43: Specific Binding of the Ligand and its Ability to Potentiate AMPAR Currents.
    Vyunova TV; Andreeva LA; Shevchenko KV; Grigoriev VV; Palyulin VA; Lavrov MI; Bondarenko EV; Kalashnikova EE; Myasoedov NF
    Curr Mol Pharmacol; 2020; 13(3):216-223. PubMed ID: 32124706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained ethanol inhibition of native AMPA receptors on medial septum/diagonal band (MS/DB) neurons.
    Frye GD; Fincher A
    Br J Pharmacol; 2000 Jan; 129(1):87-94. PubMed ID: 10694206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions among GYKI-52466, cyclothiazide, and aniracetam at recombinant AMPA and kainate receptors.
    Johansen TH; Chaudhary A; Verdoorn TA
    Mol Pharmacol; 1995 Nov; 48(5):946-55. PubMed ID: 7476926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complex pharmacological properties of recombinant alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate receptor subtypes.
    Stein E; Cox JA; Seeburg PH; Verdoorn TA
    Mol Pharmacol; 1992 Nov; 42(5):864-71. PubMed ID: 1279377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A desensitization-selective potentiator of AMPA-type glutamate receptors.
    Sekiguchi M; Nishikawa K; Aoki S; Wada K
    Br J Pharmacol; 2002 Aug; 136(7):1033-41. PubMed ID: 12145103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenosine triphosphate acts as both a competitive antagonist and a positive allosteric modulator at recombinant N-methyl-D-aspartate receptors.
    Kloda A; Clements JD; Lewis RJ; Adams DJ
    Mol Pharmacol; 2004 Jun; 65(6):1386-96. PubMed ID: 15155832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quinoxaline derivatives: structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptor-mediated currents and synaptic potentials.
    Randle JC; Guet T; Bobichon C; Moreau C; Curutchet P; Lambolez B; de Carvalho LP; Cordi A; Lepagnol JM
    Mol Pharmacol; 1992 Feb; 41(2):337-45. PubMed ID: 1371583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological characterisation of MDI-222, a novel AMPA receptor positive allosteric modulator with an improved safety profile.
    Ward SE; Harries MH; Aldegheri L; Bradford AM; Ballini E; Dawson L; Lacroix L; Pardoe J; Starr K; Weil A; Waters K; Atack JR; Woolley M
    J Psychopharmacol; 2020 Jan; 34(1):93-102. PubMed ID: 31766938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disruption of agonist and ligand activity in an AMPA glutamate receptor splice-variable domain deletion mutant.
    Johnson WD; Parandaman V; Onaivi ES; Taylor RE; Akinshola BE
    Brain Res; 2008 Jul; 1222():18-30. PubMed ID: 18585685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The new 2,3-benzodiazepine derivative EGIS-8332 inhibits AMPA/kainate ion channels and cell death.
    Vegh MG; Kovács AD; Kovács G; Szabó G; Tihanyi K; Hársing LG; Lévay G
    Neurochem Int; 2007 Feb; 50(3):555-63. PubMed ID: 17147974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.